You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Rituximab for the treatment of relapsed or refractory stage 3 or 4 follicular non-Hodgkin's lymphoma

  • Technology appraisal guidance
  • Reference number: TA137
  • Published:  27 February 2008
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

Appendix A: decision paper presented to the Institute's Guidance Executive

Appendix A: decision paper presented to the Institute's Guidance Executive Appendix A: decision paper presented to the Institute's Guidance Executive
08 March 2011
(84.25 Kb 24 sec)

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 08 March 2011

Back to top